BridgeMD
PHARMACOLOGICAL STRATEGIES OF INHALED ANTIBIOTHERAPY IN BRONCHIECTASIS WITH CHRONIC BRONCHIAL INFECTION: BRONCHIPHARMA STUDY.
EU CTIS ID: 2023-510220-72-00
What this study is testing
To evaluate if patients with chronic bronchial infection after receiving a course of targeted oral or intravenous treatment who subsequently receive treatment with inhaled antibiotics have a reduction in the colony-forming units compared to the placebo group.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Adult patients with bronchiectasis.
- Age 20 to 90 years
- Men and women alike.
- Minimum of 2 sputum cultures positive for the same germ in the last year.
- Under follow-up by the Multidisciplinary Bronchiectasis Unit of Hospital del Mar.
- Severity of bronchiectasis and exacerbations according to the current scales: BSI, FACED, EFACED.
You likely can't join if
- Inhaled/nebulized antibiotic therapy in the last year
- Adverse reactions to inhaled/nebulized antibiotics
- Inability to use the nebulization device
- Carriers of chronic home oxygen therapy
- Concomitant infection with nontuberculous mycobacteria
- In the case of women of childbearing age, a positive pregnancy test or desire for pregnancy during the period of the study
See the full eligibility criteria
- Adult patients with bronchiectasis.
- Age 20 to 90 years
- Men and women alike.
- Minimum of 2 sputum cultures positive for the same germ in the last year.
- Under follow-up by the Multidisciplinary Bronchiectasis Unit of Hospital del Mar.
- Severity of bronchiectasis and exacerbations according to the current scales: BSI, FACED, EFACED.
- All patients who meet these criteria will be included regardless of their background treatment: Inhaled corticosteroids, bronchodilators, concomitant treatment with oral antibiotics such as azithromycin and whether or not they are receiving respiratory physiotherapy.
- Provide signed and dated informed consent form.
- Be willing to comply with all study procedures and be available during the duration of the study.
- Inhaled/nebulized antibiotic therapy in the last year
- Adverse reactions to inhaled/nebulized antibiotics
- Inability to use the nebulization device
- Carriers of chronic home oxygen therapy
- Concomitant infection with nontuberculous mycobacteria
- In the case of women of childbearing age, a positive pregnancy test or desire for pregnancy during the period of the study
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.